Urolithiasis bei der Langzeitherapie mit GnRH-Agonisten bei Paraphilien – 3 Fallberichte

 

 Buy Article Permissions and Reprints

Zusammenfassung

Unter der forensischen Nachsorge-Behandlung von Sexualstraftätern mit einer Paraphilie traten in der Berliner Nachsorgeambulanz in den letzten 5 Jahren bei 3 von 32 mit GnRH-Analoga medizierten Patienten eine behandlungsbedürftige Urolithiasis auf, wobei zuvor alle 3 Patienten unter der Therapie bereits eine Osteopenie/Osteoporose entwickelt hatten. Dieser Artikel beschreibt diese 3 Fälle und schlägt eine intensivere Berücksichtigung des möglichen Auftretens von Nierensteinen bei antiandrogen behandelten Sexualstraftätern vor.

Abstract

The outpatient forensic aftercare department of the Charité Berlin treated 32 paraphilic sex offenders with GnRH analogues within the past 5 years. Out of those patients, three men suffered from urolithiasis and were in need of treatment. All 3 patients had previously developed osteopenia/osteoporosis while on antiandrogen treatment.

This article describes these 3 cases and suggests an intense consideration of the possible occurrence of urolithiasis in sex offenders on antiandrogen treatment.

• Literatur

• 1 Lee JY, Cho KS. Chemical castration for sexual offenders: physicians’ views. J Korean Med Sci 2013; 28: 171-172
  CrossrefPubMedGoogle Scholar
• 2 Turner D, Basdekis-Jozsa R, Briken P. Prescription of testosterone-lowering medications for sex offender treatment in German forensic-psychiatric institutions. J Sex Med 2013; 10: 570-578
  CrossrefPubMedGoogle Scholar
• 3 Voß T, Klemke K, Schneider-Njepel V et al. Wenn ja, wie lange? – Zur Dauer antiandrogener Behandlung von Sexualstraftätern mit paraphilen Störungen. Eingereicht zur Veröffentlichung FPPK 2015
  PubMed
• 4 Thibaut F. Pharmacological treatment of paraphilias. Isr J Psychiatry Relat Sci 2012; 49: 297-305
  PubMedGoogle Scholar
• 5 Lösel F, Schmucker M. The effectiveness of treatment for sexual offenders: a comprehensive meta-analysis. J Exp Criminol 2005; 1: 117-146
  CrossrefPubMedGoogle Scholar
• 6 Lieske JC, Peña de la Vega LS, Slezak JM et al. Renal stone epidemiology in Rochster, Minnesota: an update. Kidney Int 2006; 69: 760-764
  CrossrefPubMedGoogle Scholar
• 7 Long LO, Park S. Update on nephrolithiasis management. Minerva urol Nefrol 2007; 59: 317-325
  PubMedGoogle Scholar
• 8 Stamatelou KK, Francis ME, Jones CA et al. Time trends in reported prevalence of kidney stones in the United States: 1976–1994. Kidney Int 2003; 63: 1817-1823
  CrossrefPubMedGoogle Scholar
• 9 Herold G. Herold Innere Medizin 2013; 2013: 653-656
  PubMed
• 10 Türk C, Knoll T, Petrik A. EAU guidelines on urolithiasis. 2014 www.uroweb.org
  PubMedGoogle Scholar
• 11 Jocham D, Miller K, Bares R et al. 2007 Praxis der Urologie Band I.
  PubMedGoogle Scholar
• 12 Fisang C, Anding R, Müller SC et al. Urolithiasis – interdisziplinäre Herausforderung in Diagnostik, Therapie und Metaphylaxe. Dtsch Arztebl 2015; 112: 83-91
  PubMedGoogle Scholar
• 13 Coe FL, Parks JH, Asplin JR et al. The pathogenesis and treatment of kidney stones. N. Engl J Med 1992; 327: 1141-1152
  CrossrefPubMedGoogle Scholar
• 14 Sabbagh R. Bones and stones – The link between opsteoporosis and nephrolithiasis. Osteoporosis Update 2009; 13: 5-7
  PubMedGoogle Scholar
• 15 Izzedine H, Lescure FX, Bonnet F. HIV medication-based urolithiasis. Clin Kidney J. 2014; 7: 121-126
  CrossrefPubMedGoogle Scholar
• 16 Audran M, Legrand E. Hypercalciuria. Joint Bone Spine 2000; 67: 509-515
  CrossrefPubMedGoogle Scholar
• 17 Cauley JA, Fullman RL, Stone KL et al. Factors associated with the lumbar spine and proximal femur bone mineral density in older men. Osteoporos Int 2005; 16: 1525-1537
  CrossrefPubMedGoogle Scholar
• 18 Denburg MR, Leonard MB, Haynes K et al. Risk of fracture in urolithiasis: A population-based cohort study using the health improvement network. Clin J Am Soc Nephrol 2014; 9: 2133-2140
  CrossrefPubMedGoogle Scholar
• 19 Sakhaee K, Maalouf NM, Kumar R et al. Nephrolithiasis-associated bone disease: pathogenesis and treatment options. Kidney Int 2011; 79: 393-403
  CrossrefPubMedGoogle Scholar
• 20 Trinchieri Nespoli R, Ostini F. et al. A study of dietary calcium and other nutrients in idiopathic renal calcium stone formers with low bone mineral content. J Urol 2002; 159: 654-657
  PubMedGoogle Scholar
• 21 Keller JJ, Lin CC, Kang JH et al. Association between osteoporosis and urinary calculus: evidence from a population-based study. Osteoporos Int 2013; 24: 651-657
  CrossrefPubMedGoogle Scholar
• 22 Giltay EJ, Gooren LJ. Potential side effects of androgen deprivation treatment in sex offenders. J Am Acad Psychiatry Law 2009; 37: 53-58
  PubMedGoogle Scholar
• 23 Moe OW. Kidney stones: Pathophysiology and medical management. Lancet 2006; 367: 333-344
  CrossrefPubMedGoogle Scholar
• 24 Mohile SG, Mustian K, Bylow K et al. Management of complications of androgen deprivation therapy in the older man. Oncology/Hepatology 2009; 70: 235-255
  PubMedGoogle Scholar
• 25 Lee YH, Huang WC, Huang JK et al. Testosteron enhances whereas estrogen inhibits calcium oxalate stone formation in ethylene glycol treated rats. J Urol 1996 Aug 1992; 156 2Pt1 502-505
  PubMedGoogle Scholar
• 26 Yagisawa T, Ito F, Osaka Y et al. The influence of sex hormones on renal osteopontin expression and urinary constituents in experimental urolithiasis. J Urol 2001; 166: 1078-1082
  CrossrefPubMedGoogle Scholar